However, chemotherapy has always come with toxicity issues, a problem that scientists intend to tackle head-on. HER2+ breast cancer is a common subtype of breast cancer with a standard treatment of ...

Trastuzumab treatment could be continued at the investigator's discretion while capecitabine was being withheld. Specific recommendations for dose modification were provided for diarrhea of grade ≥ 2, ...

"Our study evaluated the skin toxicity and early cardiac toxicity of concurrent Trastuzumab and radiation therapy treatment in the adjuvant setting," says Penny Anderson, M.D., radiation ...

Lapatinib was permanently discontinued for any grade 4 toxicity. No dose adjustment was foreseen for trastuzumab. LVEF was evaluated before ... mainly because of diarrhea and skin toxicities. However, ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

"It's not only the response rate which is indeed numerically much higher, but it is the lower toxicity of this drug compared to traditional chemotherapies and Herceptin," she added. T-DM1 is the ...

The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves ... febrile neutropenia, and dry skin were higher by at least 5 percentage points ...

is another type of trastuzumab treatment that is injected underneath the skin. Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy.

In their study, Dr. Guarneri and colleagues retrospectively assessed the cardiac toxicity of trastuzumab in 173 patients with advanced breast cancer treated with the drug for at least 1 year ...

Back to Healio Weekly adjuvant treatment with paclitaxel and trastuzumab lead to low incidence of grade 3 or grade 4 left ventricular systolic dysfunction and asymptomatic left ventricular ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...

Subcutaneous administration of trastuzumab and pertuzumab significantly ... and shortened the workflow for the pharmacy. “Time toxicity doesn’t get talked about enough,” Adrienne G.